| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Leonor Sterin-Borda, Claudia F Del Zar, Enri Bord. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. Biochemical pharmacology. vol 69. issue 12. 2005-07-19. PMID:15885656. |
differential cb1 and cb2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. |
2005-07-19 |
2023-08-12 |
rat |
| Leonor Sterin-Borda, Claudia F Del Zar, Enri Bord. Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. Biochemical pharmacology. vol 69. issue 12. 2005-07-19. PMID:15885656. |
data give pharmacological evidence for the existence of functional cb1 and cb2 cannabinoid receptors in rat isolated atria and may contribute to a better understanding the effects of cannabinoids in the cardiovascular system. |
2005-07-19 |
2023-08-12 |
rat |
| Luigi F Rodella, Elisa Borsani, Rita Rezzani, Francesca Ricci, Barbara Buffoli, Rossella Bianch. AM404, an inhibitor of anandamide reuptake decreases Fos-immunoreactivity in the spinal cord of neuropathic rats after non-noxious stimulation. European journal of pharmacology. vol 508. issue 1-3. 2005-07-14. PMID:15680264. |
co-administration of cannabinoid cb1 receptor, cannabinoid cb2 receptor and transient receptor potential vanilloid type 1 (trpv-1) antagonists reduced the effect of am404 and this reduction was higher using cannabinoid cb1 receptor antagonist. |
2005-07-14 |
2023-08-12 |
rat |
| Luigi F Rodella, Elisa Borsani, Rita Rezzani, Francesca Ricci, Barbara Buffoli, Rossella Bianch. AM404, an inhibitor of anandamide reuptake decreases Fos-immunoreactivity in the spinal cord of neuropathic rats after non-noxious stimulation. European journal of pharmacology. vol 508. issue 1-3. 2005-07-14. PMID:15680264. |
these results suggest that am404 could be a useful drug to reduce neuropathic pain and that cannabinoid cb1 receptor, cannabinoid cb2 receptor and vanilloid trpv-1 receptor are involved. |
2005-07-14 |
2023-08-12 |
rat |
| F Gambi, D De Berardis, G Sepede, R Quartesan, E Calcagni, R M Salerno, C M Conti, F M Ferr. Cannabinoid receptors and their relationships with neuropsychiatric disorders. International journal of immunopathology and pharmacology. vol 18. issue 1. 2005-07-14. PMID:15698507. |
to date, two cannabinoid receptors have been cloned, cb1 and cb2. |
2005-07-14 |
2023-08-12 |
Not clear |
| Palmiero Monteleone, Isabelle Matias, Vassilis Martiadis, Luciano De Petrocellis, Mario Maj, Vincenzo Di Marz. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 30. issue 6. 2005-07-11. PMID:15841111. |
the endocannabinoid system, consisting of two cannabinoid receptors (cb1 and cb2) and the endogenous ligands anandamide (arachidonoylethanolamide (aea)) and 2-arachidonoylglycerol (2-ag), has been shown to control food intake in both animals and humans, modulating either rewarding or quantitative aspects of the eating behavior. |
2005-07-11 |
2023-08-12 |
Not clear |
| Barbara L F Kaplan, Yanli Ouyang, Amy Herring, Sung Su Yea, Raj Razdan, Norbert E Kaminsk. Inhibition of leukocyte function and interleukin-2 gene expression by 2-methylarachidonyl-(2'-fluoroethyl)amide, a stable congener of the endogenous cannabinoid receptor ligand anandamide. Toxicology and applied pharmacology. vol 205. issue 2. 2005-07-07. PMID:15893538. |
arachidonylethanolamide (anandamide, aea) has been identified as an endogenous ligand for cannabinoid receptors cb1 and cb2. |
2005-07-07 |
2023-08-12 |
Not clear |
| Kenneth J Valenzano, Laykea Tafesse, Gary Lee, James E Harrison, Jamie M Boulet, Susan L Gottshall, Lilly Mark, Michelle S Pearson, Wendy Miller, Shen Shan, Leyana Rabadi, Yakov Rotshteyn, Suzanne M Chaffer, Paul I Turchin, David A Elsemore, Mathew Toth, Lee Koetzner, Garth T Whitesid. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology. vol 48. issue 5. 2005-06-24. PMID:15814101. |
to date, two cannabinoid receptors have been identified, cb1 and cb2. |
2005-06-24 |
2023-08-12 |
human |
| Kenneth J Valenzano, Laykea Tafesse, Gary Lee, James E Harrison, Jamie M Boulet, Susan L Gottshall, Lilly Mark, Michelle S Pearson, Wendy Miller, Shen Shan, Leyana Rabadi, Yakov Rotshteyn, Suzanne M Chaffer, Paul I Turchin, David A Elsemore, Mathew Toth, Lee Koetzner, Garth T Whitesid. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology. vol 48. issue 5. 2005-06-24. PMID:15814101. |
for the first time, we show that gw405833 selectively binds both rat and human cb2 receptors with high affinity, where it acts as a partial agonist (approximately 50% reduction of forskolin-mediated camp production compared to the full cannabinoid agonist, cp55,940). |
2005-06-24 |
2023-08-12 |
human |
| Kenneth J Valenzano, Laykea Tafesse, Gary Lee, James E Harrison, Jamie M Boulet, Susan L Gottshall, Lilly Mark, Michelle S Pearson, Wendy Miller, Shen Shan, Leyana Rabadi, Yakov Rotshteyn, Suzanne M Chaffer, Paul I Turchin, David A Elsemore, Mathew Toth, Lee Koetzner, Garth T Whitesid. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology. vol 48. issue 5. 2005-06-24. PMID:15814101. |
these data support the tenet that selective cb2 receptor agonists have the potential to treat pain without eliciting the centrally-mediated side effects associated with non-selective cannabinoid agonists, and highlight the utility of gw405833 for the investigation of cb2 physiology. |
2005-06-24 |
2023-08-12 |
human |
| Brian J Lavey, Joseph A Kozlowski, R William Hipkin, Waldemar Gonsiorek, Daniel J Lundell, John J Piwinski, Satwant Narula, Charles A Lun. Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies. Bioorganic & medicinal chemistry letters. vol 15. issue 3. 2005-06-07. PMID:15664857. |
triaryl bis-sulfones as a new class of cannabinoid cb2 receptor inhibitors: identification of a lead and initial sar studies. |
2005-06-07 |
2023-08-12 |
Not clear |
| Brian J Lavey, Joseph A Kozlowski, R William Hipkin, Waldemar Gonsiorek, Daniel J Lundell, John J Piwinski, Satwant Narula, Charles A Lun. Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies. Bioorganic & medicinal chemistry letters. vol 15. issue 3. 2005-06-07. PMID:15664857. |
a novel class of cannabinoid cb2 receptor ligands is described. |
2005-06-07 |
2023-08-12 |
Not clear |
| Brian J Lavey, Joseph A Kozlowski, R William Hipkin, Waldemar Gonsiorek, Daniel J Lundell, John J Piwinski, Satwant Narula, Charles A Lun. Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies. Bioorganic & medicinal chemistry letters. vol 15. issue 3. 2005-06-07. PMID:15664857. |
these triaryl bis-sulfones are nanomolar inhibitors of the cb2 receptor and show high selectivity over the cannabinoid cb1 receptor. |
2005-06-07 |
2023-08-12 |
Not clear |
| Cristina Montero, Nuria Eugenia Campillo, Pilar Goya, Juan Antonio Páe. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study. European journal of medicinal chemistry. vol 40. issue 1. 2005-06-02. PMID:15642412. |
homology models of the cannabinoid cb1 and cb2 receptors. |
2005-06-02 |
2023-08-12 |
human |
| Sören V Siegmund, Hiroshi Uchinami, Yosuke Osawa, David A Brenner, Robert F Schwab. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology (Baltimore, Md.). vol 41. issue 5. 2005-06-01. PMID:15841466. |
although the putative endocannabinoid receptors cb1, cb2, and vr1 were expressed in hscs, specific receptor blockade failed to block cell death. |
2005-06-01 |
2023-08-12 |
Not clear |
| Sutapa Mukherjee, Monique Adams, Kristi Whiteaker, Anthony Daza, Karen Kage, Steven Cassar, Michael Meyer, Betty Bei Ya. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. European journal of pharmacology. vol 505. issue 1-3. 2005-05-16. PMID:15556131. |
species comparison and pharmacological characterization of rat and human cb2 cannabinoid receptors. |
2005-05-16 |
2023-08-12 |
human |
| Sutapa Mukherjee, Monique Adams, Kristi Whiteaker, Anthony Daza, Karen Kage, Steven Cassar, Michael Meyer, Betty Bei Ya. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. European journal of pharmacology. vol 505. issue 1-3. 2005-05-16. PMID:15556131. |
pharmacological effects of cannabinoid ligands are thought to be mediated through cannabinoid cb1 and cb2 receptor subtypes. |
2005-05-16 |
2023-08-12 |
human |
| Sutapa Mukherjee, Monique Adams, Kristi Whiteaker, Anthony Daza, Karen Kage, Steven Cassar, Michael Meyer, Betty Bei Ya. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. European journal of pharmacology. vol 505. issue 1-3. 2005-05-16. PMID:15556131. |
sequence analysis revealed that rat and human cannabinoid cb2 receptors are divergent and share 81% amino acid homology. |
2005-05-16 |
2023-08-12 |
human |
| Sutapa Mukherjee, Monique Adams, Kristi Whiteaker, Anthony Daza, Karen Kage, Steven Cassar, Michael Meyer, Betty Bei Ya. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. European journal of pharmacology. vol 505. issue 1-3. 2005-05-16. PMID:15556131. |
pharmacological analysis of the possible species differences between rat and human cannabinoid cb2 receptors was performed using radioligand binding and functional assays. |
2005-05-16 |
2023-08-12 |
human |
| Sutapa Mukherjee, Monique Adams, Kristi Whiteaker, Anthony Daza, Karen Kage, Steven Cassar, Michael Meyer, Betty Bei Ya. Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. European journal of pharmacology. vol 505. issue 1-3. 2005-05-16. PMID:15556131. |
pronounced species selectivity at the rat cannabinoid cb2 receptor (50- to 140-fold) was observed with am-1710 (3-(1,1-dimethyl-heptyl)-1-hydroxy-9-methoxy-benzo[c]chromen-6-one) and am-1714 (3-(1,1-dimethyl-heptyl)-1-9-dihydroxy-benzo[c]chromen-6-one). |
2005-05-16 |
2023-08-12 |
human |